Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 1, 2014, Pages 85-93

  Golabchifar, Ali Akbar ^a   Rezaee, Saeed ^b   Ghavamzadeh, Ardeshir ^c   Alimoghaddam, Kamran ^c   Dinan, Nahid Mobarghei ^a   Rouini, Mohammad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic myeloid leukemia; Imatinib; Population pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

IMATINIB;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; COMPARTMENT MODEL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; FEMALE; GENETIC VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IRANIAN PEOPLE; LIMIT OF QUANTITATION; LIQUID LIQUID EXTRACTION; MALE; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; POPULATION PHARMACOKINETICS; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STEADY STATE; ULTRAVIOLET RADIATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BAYES THEOREM; BENZAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FUSION PROTEINS, BCR-ABL; HUMANS; IRAN; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; ROC CURVE; YOUNG ADULT;

EID: 84903814879     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2473-1     Document Type: Article

References (21)

1. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56(1):100-104
2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR- ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031-1037 (Pubitemid 32267972)
3. Wang Y, Chia YL, Nedelman J, Schran H, Mahon FX, Molimard M (2009) A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. Ther Drug Monit 31(5):579-584
4. Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44(9):879-894 (Pubitemid 41252840)
5. Gandia P, Arellano C, Lafont T, Huguet F, Malard L, Chatelut E (2012) Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethylimatinib be developed? Cancer Chemother Pharmacol 71(2):531- 536. doi:10.1007/s00280-012-2035-3
6. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, Lassalle R, Marit G, Reiffers J, Begaud B, Moore N, Molimard M, Mahon FX (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standarddose imatinib in chronic myeloid leukemia. Blood 109(8):3496-3499. doi:10.1182/blood-2006-07-036012 (Pubitemid 46572540)
7. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111(8):4022-4028. doi:10.1182/blood-2007-10-116475
8. Awidi A, Ayed AO, Bsoul N, Magablah A, Mefleh R, Dweiri M, Ramahi M, Arafat E, Bishtawi M, Marie L (2010) Relationship of serum imatinib trough level and response in CML patients: long term follow-up. Leuk Res 34(12):1573-1575. doi:10.1016/j.leukres.2010.07.014
9. Gotta V, Widmer N, Montemurro M, Leyvraz S, Haouala A, Decosterd LA, Csajka C, Buclin T (2012) Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels. Clin Pharmacokinet 51(3):187-201. doi:10.2165/11596990-000000000-00000
10. Sheiner LB, Beal S, Rosenberg B, Marathe VV (1979) Forecasting individual pharmacokinetics. Clin Pharmacol Ther 26(3):294-305 (Pubitemid 10194671)
11. Samara E, Granneman R (1997) Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective. Clin Pharmacokinet 32(4):294-312 (Pubitemid 27160612)
12. Williams PJ, Ette EI (2000) The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's 'Guidance for Industry: population pharmacokinetics'. Clin Pharmacokinet 39(6):385-395 (Pubitemid 32099467)
13. Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Geoerger B, Barrois M, Seronie-Vivien S, LeCesne A, Vassal G (2008) Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 14(21):7102-7109. doi:10.1158/1078-0432. CCR-08-0950
14. Schmidli H, Peng B, Riviere GJ, Capdeville R, Hensley M, Gathmann I, Bolton AE, Racine-Poon A (2005) Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol 60(1):35-44 (Pubitemid 40942779)
15. Faber E, Friedecky D, Micova K, Rozmanova S, Divoka M, Jarosova M, Indrak K, Adam T (2012) Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting. Ann Hematol 91(6):923-929. doi:10.1007/s00277-011-1394-x
16. Golabchifar A, Rouini MR, Shafaghi B, Rezaee S, Foroumadi A, Khoshayand MR (2011) Optimization of the simultaneous determination of imatinib and its major metabolite, CGP74588, in human plasma by a rapid HPLC method using D-optimal experimental design. Talanta 85(5):2320-2329. doi:10.1016/j.talanta. 2011.07.093
17. Ette EI, Sun H, Ludden TM (1998) Balanced designs in longitudinal population pharmacokinetic studies. J Clin Pharmacol 38(5):417-423 (Pubitemid 28224213)
18. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108(1):28-37. doi:10.1182/blood-2006-01-0092 (Pubitemid 43990609)
19. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349(15):1423-1432. doi:10.1056/NEJMoa030513349/15/1423 (Pubitemid 37211057)
20. Holford NH (1999) Target concentration intervention: beyond Y2K. Br J Clin Pharmacol 48(1):9-13
21. Menon-Andersen D, Mondick JT, Jayaraman B, Thompson PA, Blaney SM, Bernstein M, Bond M, Champagne M, Fossler MJ, Barrett JS (2008) Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol. doi:10.1007/s00280-008-0730-x